首页> 外文期刊>Pharmacogenetics and genomics >The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.
【24h】

The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.

机译:代谢酶和转运蛋白的药物遗传学对替米沙坦在健康志愿者中的药代动力学的影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: Telmisartan is mainly taken up into the liver by organic anion transporting polypeptide (OATP) 1B3, conjugated with glucuronate, and excreted into the bile. We investigated the relationship between genotypes of metabolizing enzymes and transporters and pharmacokinetics of telmisartan in clinical study. We also checked which enzymes are responsible for telmisartan glucuronidation. MATERIALS AND METHODS: We collected blood samples from 57 healthy volunteers who had participated in a clinical trial of telmisartan and examined the relationship between 14 mutations in six transporters/metabolic enzymes and pharmacokinetics of telmisartan. We also performed an in-vitro glucuronidation assay with recombinant uridine 5'-diphospho-glucuronosyltransferases isoforms and human liver microsomes. RESULTS: In the clinical study, area under the plasma concentration-time curve value from time zero to infinity, of telmisartan in heterozygotes of SLCO1B3 (encoding protein: OATP1B3) rs11045585 tended to be larger than that in homozygotes of wild-type alleles. Unexpectedly, 19 heterozygotes of UGT1A1*28, whose function was decreased, significantly increased its oral clearance compared with homozygotes of UGT1A1*1 alleles (1090+/-690 vs. 620+/-430 ml/min/body). Metabolic clearance of telmisartan in human liver microsomes obtained from individuals with UGT1A1*28/*28 was higher compared with that of UGT1A1*1/*1 (168+/-33 vs. 93.3+/-27.3 mul/min/mg protein). Although telmisartan was metabolized by multiple UGT isoforms, in-vitro experiments revealed that UGT1A3 was estimated to be predominantly involved in telmisartan glucuronidation in human hepatocytes. CONCLUSION: UGT1A1*28 was thought to enhance the protein expression of UGT1A3 as reported most recently (Riedmaier et al. Clin Pharmacol Ther 2010; 87:65-73) and thereby increase glucuronidation activity of telmisartan and decrease the plasma concentration of telmisartan.
机译:目的:替米沙坦主要通过有机阴离子转运多肽(OATP)1B3吸收到肝脏中,与葡萄糖醛酸结合后排泄到胆汁中。在临床研究中,我们研究了代谢酶和转运蛋白的基因型与替米沙坦药代动力学之间的关系。我们还检查了负责替米沙坦葡萄糖醛酸化的酶。材料与方法:我们从57名参加替米沙坦临床试验的健康志愿者那里采集了血样,并研究了6种转运蛋白/代谢酶中14种突变与替米沙坦药代动力学之间的关系。我们还用重组尿苷5'-二磷酸-葡萄糖醛酸糖基转移酶同工型和人肝微粒体进行了体外葡萄糖醛酸化试验。结果:在临床研究中,在SLCO1B3(编码蛋白:OATP1B3)rs11045585杂合子中,替米沙坦的血浆浓度-时间曲线值从零时到无限远的面积倾向于大于野生型等位基因纯合子中的浓度。出乎意料的是,与UGT1A1 * 1等位基因的纯合子相比,功能降低的19个UGT1A1 * 28杂合子的口腔清除率显着增加(1090 +/- 690对620 +/- 430 ml / min /体)。从具有UGT1A1 * 28 / * 28的个体获得的人肝微粒体中替米沙坦的代谢清除率高于UGT1A1 * 1 / * 1(168 +/- 33对93.3 +/- 27.3 mul / min / mg蛋白) 。尽管替米沙坦被多种UGT亚型代谢,但体外实验显示,UGT1A3估计主要参与人肝细胞中替米沙坦的葡萄糖醛酸化。结论:据最近报道,UGT1A1 * 28被认为可以增强UGT1A3的蛋白表达(Riedmaier等人,Clin Pharmacol Ther 2010; 87:65-73),从而增加替米沙坦的葡萄糖醛酸化活性,并降低替米沙坦的血浆浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号